Digest Network Come funziona
Network
/
Società
TR
Non verificato

TRex Bio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

10 comunicati stampa

Guarda tutti i comunicati
26/08/2026
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
30/06/2026
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
29/04/2026
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
27/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
03/09/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
TRexBio to Participate in Upcoming Investor Conferences in September
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
03/06/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
08/04/2025
Mercato del lavoro
Scienza
Biotecnologia
Sanità
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
13/11/2024
Mercato del lavoro
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0
26/06/2024
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sanità
TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
Fonte
TRex Bio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0